Literature DB >> 27612856

Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.

Isabelle Matte1, Clara Major Legault1, Perrine Garde-Granger2, Claude Laplante2, Paul Bessette3, Claudine Rancourt1, Alain Piché4.   

Abstract

Epithelial ovarian cancer (EOC) dissemination is primarily mediated by the shedding of tumor cells from the primary site into ascites where they form multicellular spheroids that rapidly lead to peritoneal carcinomatosis. While the clinical importance and fundamental role of multicellular spheroids in EOC is increasingly appreciated, the mechanisms that regulate their formation and dictate their cellular composition remain poorly characterized. To investigate these important questions, we characterized spheroids isolated from ascites of women with EOC. We found that in these spheroids, a core of mesothelial cells was encased in a shell of tumor cells. Analysis further revealed that EOC spheroids are dynamic structures of proliferating, non-proliferating and hypoxic regions. To recapitulate these in vivo findings, we developed a three-dimensional co-culture model of primary EOC and mesothelial cells. Our analysis indicated that, compared to the OVCAR3 cell line, primary EOC cells isolated from ascites as well as mesothelial cells formed compact spheroids. Analysis of heterotypic spheroid microarchitecture revealed a structure that grossly resembles the structure of spheroids isolated from ascites. Cells that formed compact spheroids had elevated expression of β1 integrin and low expression of E-cadherin. Addition of β1 integrin blocking antibody or siRNA-mediated downregulation of β1 integrin resulted in reduced tightness of the spheroids. Interestingly, the loss of MUC16 and E-cadherin expression resulted in the formation of more compact spheroids. Therefore, our findings support the heterotypic nature of spheroids from malignant EOC ascites. In addition, our data describe an unusual link between E-cadherin expression and less compact spheroids. Our data also emphasize the role of MUC16 and β1 integrin in EOC spheroid formation.

Entities:  

Keywords:  3D culture; Mesothelial cells; Ovarian cancer; Spheroids

Mesh:

Substances:

Year:  2016        PMID: 27612856     DOI: 10.1007/s10585-016-9821-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  47 in total

Review 1.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.

Authors:  Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

2.  MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Authors:  Panagiota Giannakouros; Marina Comamala; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 3.  Epithelial ovarian cancer: prevention, diagnosis, and treatment.

Authors:  E E Partridge; M N Barnes
Journal:  CA Cancer J Clin       Date:  1999 Sep-Oct       Impact factor: 508.702

4.  Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients.

Authors:  Trevor G Shepherd; Brigitte L Thériault; Elizabeth J Campbell; Mark W Nachtigal
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  Diversity of cell-mediated adhesions in breast cancer spheroids.

Authors:  Andrea Ivascu; Manfred Kubbies
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

6.  Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.

Authors:  Kenjiro Sawada; Anirban K Mitra; A Reza Radjabi; Vinay Bhaskar; Emily O Kistner; Maria Tretiakova; Sujatha Jagadeeswaran; Anthony Montag; Amy Becker; Hilary A Kenny; Marcus E Peter; Vanitha Ramakrishnan; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 7.  Multicellular spheroids in ovarian cancer metastases: Biology and pathology.

Authors:  Kristy Shield; M Leigh Ackland; Nuzhat Ahmed; Gregory E Rice
Journal:  Gynecol Oncol       Date:  2009-01-10       Impact factor: 5.482

8.  Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype.

Authors:  Katharine L Sodek; Maurice J Ringuette; Theodore J Brown
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

9.  Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.

Authors:  Fei Wang; Rhonda K Hansen; Derek Radisky; Toshiyuki Yoneda; Mary Helen Barcellos-Hoff; Ole W Petersen; Eva A Turley; Mina J Bissell
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

10.  Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.

Authors:  M Comamala; M Pinard; C Thériault; I Matte; A Albert; M Boivin; J Beaudin; A Piché; C Rancourt
Journal:  Br J Cancer       Date:  2011-02-15       Impact factor: 7.640

View more
  14 in total

1.  Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials.

Authors:  Hong Song; Guo-Hui Cai; Jian Liang; Di-Shu Ao; Huan Wang; Ze-Hong Yang
Journal:  J Nanobiotechnology       Date:  2020-06-11       Impact factor: 10.435

2.  Multicellular Tumor Spheroids in Nanomedicine Research: A Perspective.

Authors:  Martina Rossi; Paolo Blasi
Journal:  Front Med Technol       Date:  2022-06-15

Review 3.  Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components.

Authors:  Militsa Rakina; Anna Kazakova; Alisa Villert; Larisa Kolomiets; Irina Larionova
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

Review 4.  The untapped potential of ascites in ovarian cancer research and treatment.

Authors:  Caroline Elizabeth Ford; Bonnita Werner; Neville Frederick Hacker; Kristina Warton
Journal:  Br J Cancer       Date:  2020-05-08       Impact factor: 7.640

5.  SERS-based detection of haptoglobin in ovarian cyst fluid as a point-of-care diagnostic assay for epithelial ovarian cancer.

Authors:  Jayakumar Perumal; Aniza Puteri Mahyuddin; Ghayathri Balasundaram; Douglas Goh; Chit Yaw Fu; Agne Kazakeviciute; U S Dinish; Mahesh Choolani; Malini Olivo
Journal:  Cancer Manag Res       Date:  2019-01-31       Impact factor: 3.989

6.  Novel strategy of ovarian cancer implantation: Pre-invasive growth of fibrin-anchored cells with neovascularization.

Authors:  Ayumi Matsuoka; Yasunari Mizumoto; Masanori Ono; Kyosuke Kagami; Takeshi Obata; Junpei Terakawa; Yoshiko Maida; Mitsuhiro Nakamura; Takiko Daikoku; Hiroshi Fujiwara
Journal:  Cancer Sci       Date:  2019-07-09       Impact factor: 6.716

Review 7.  Ovarian Biomechanics: From Health to Disease.

Authors:  Chenchen Sun; Xiaoxu Yang; Tianxiao Wang; Min Cheng; Yangyang Han
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

8.  Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin-1/β-arr1 Axis.

Authors:  Danila Del Rio; Ilenia Masi; Valentina Caprara; Francesca Spadaro; Flavia Ottavi; Raffaele Strippoli; Pilar Sandoval; Manuel López-Cabrera; Ricardo Sainz de la Cuesta; Anna Bagnato; Laura Rosanò
Journal:  Front Cell Dev Biol       Date:  2021-12-01

9.  Fibronectin Regulates the Dynamic Formation of Ovarian Cancer Multicellular Aggregates and the Expression of Integrin Receptors

Authors:  Lin Gong; Ying Zheng; Shanling Liu; Zhilan Peng
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26

10.  Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells.

Authors:  Sonia Capellero; Jessica Erriquez; Chiara Battistini; Roberta Porporato; Giulia Scotto; Fulvio Borella; Maria F Di Renzo; Giorgio Valabrega; Martina Olivero
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.